Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia

Charles Koller, B. Nebiyou Bekele, Xian Zhou, Charles Park, Zeev Estrov, Susan O'Brien, Michael Keating, Iman Jilani, Francis J. Giles, Hagop M. Kantarjian, Maher Albitar*

*Corresponding author for this work

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

We investigated the association of plasma thrombopoietin (TPO) and overall survival in 127 patients with previously treated and previously untreated chronic lymphocytic leukemia (CLL). Higher levels of TPO were associated with advanced Rai stage (P < .001), higher levels of β2- microglobulin (β2-M) (P < .001), and the absence of mutation in the immunoglobulin heavy chain variable region (IgVH) (P < .001), and were inversely correlated with platelet count (P < .002). We found that TPO correlated strongly in a continuous manner with overall survival in both previously treated and untreated patients. The univariate Cox proportional hazard model demonstrated that high TPO levels were associated with shorter survival (P < .001), and multiple variable Cox proportional hazards regression analysis demonstrated that this was independent of the IgV H mutation status, β2-M, and Rai stage. Recursive partitioning showed that a cutoff point of 639 pg/mL separated the CLL patients into 2 major survival groups (P < .001). The effects of β2-M were masked by the effects of TPO in the patients with TPO levels higher than 639 pg/mL, but in the remainder, patients with β2-M level higher than 4.95 mg/L had significantly shorter survival than those with lower values. Plasma TPO and β2-M may be useful for the prediction of clinical behavior in CLL and may replace the need for the determination of IgVH mutation status.

Original languageEnglish (US)
Pages (from-to)1001-1006
Number of pages6
JournalBlood
Volume108
Issue number3
DOIs
StatePublished - Aug 1 2006

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia'. Together they form a unique fingerprint.

  • Cite this

    Koller, C., Bekele, B. N., Zhou, X., Park, C., Estrov, Z., O'Brien, S., Keating, M., Jilani, I., Giles, F. J., Kantarjian, H. M., & Albitar, M. (2006). Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia. Blood, 108(3), 1001-1006. https://doi.org/10.1182/blood-2005-05-2110